Evidence map›Paper›PMID 36915376›Full record

ArticleInternational journal of endocrinology2023

Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies.

Lingna Li, Jianing Huang, Tongmin Huang, Jie Yao, Yeyuan Zhang, Meiling Chen, Haojie Shentu, Haiying Lou

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Lingna LiPharmacy Department, The Affiliated Hospital of Ningbo University, Li Huili Hospital, Ningbo, China.ORCID https://orcid.org/0009-0005-6683-220X
Jianing HuangSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0003-3494-2285
Tongmin HuangThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-7720-4122
Jie YaoSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0003-4358-0511
Yeyuan ZhangSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-0774-7225
Meiling ChenSchool of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0003-3569-0489
Haojie ShentuSchool of Medical Imaging, Hangzhou Medical College, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-6148-3363
Haiying LouDepartment of Endocrinology, Zhuji People's Hospital, Shaoxing, Zhejiang, China.ORCID https://orcid.org/0009-0003-0272-1522
Zhejiang Chinese Medical University · CNHangzhou Medical College · CNNingbo University · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metformin is one of the most common drugs for type 2 diabetes mellitus (T2DM) treatment. In addition, metformin intends to have a positive effect on the prognosis of several cancers. However, the therapeutic effect of metformin on gastric cancer (GC) remains controversial. This study explores and updates the therapeutic effect of metformin in GC patients with T2DM. Methods: We searched through PubMed, Embase, Web of Science, and the Cochrane Library for relevant articles by July 2022. The relationship between metformin therapy and the prognosis of GC patients with T2DM was evaluated based on the hazard ratio (HR) at a 95% confidence interval (95% CI). Overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS) were the primary outcomes analyzed. Results: Seven retrospective cohort studies with a combined 2,858 patients met the inclusion criteria. OS and CSS were reported in six studies, and PFS was reported in four studies. Pooled results showed that, compared to the nonmetformin group, the prolonged OS (HR = 0.72, Conclusion: Metformin may have a beneficial effect on the prognosis of GC patients with T2DM.

Identifiers

PMID36915376
PMCPMC10008112
OpenAlexW4323074006

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read16
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.